BC
KURA icon

Birchview Capital’s Kura Oncology KURA Stock Holding History

Birchview Capital’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-59,114
Closed -$369K – 42
2016
Q3 		$369K Hold
59,114
– – 0.22% 27
2016
Q2 		$160K Sell
59,114
-20,000
-25% -$62.2K 0.12% 37
2016
Q1 		$320K Sell
79,114
-26,171
-25% -$124K 0.23% 28
2015
Q4 		$884K Buy
+105,285
New +$829K 0.51% 15

Other funds holding KURA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Birchview Capital's KURA Position: Q4 2016 in Review

Birchview Capital sold out of Kura Oncology (KURA) in Q4 2016, closing a stake of 59,114 shares — an estimated $369K sold.

Birchview Capital first reported a position in KURA in Q4 2015 and held it in 4 quarters. The position peaked at $884K in Q4 2015. 30 funds tracked by Wall St. Rank hold KURA as of Q4 2016.

  • Birchview Capital reported no remaining Kura Oncology position as of Q4 2016 after selling out during the quarter.
  • Birchview Capital sold 59,114 Kura Oncology shares in Q4 2016, an estimated $369K.
  • Birchview Capital first reported a position in Kura Oncology in Q4 2015 and held it in 4 quarters.
  • Birchview Capital's Kura Oncology position peaked at $884K in Q4 2015.
  • 30 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2016.

Based on Birchview Capital's 13F filing for Q4 2016, filed 9 Feb 2017.